Investor Relations

Latest News

View Press Release
View All News

Latest Financial Results

Q1 2021

Quarter Ended Mar 31, 2021
Earnings Release
PDF HTML
Audio
Earnings Webcast
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Report Links

Company Overview

Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes cancer drug compounds such as AS1411, AS1411-GNP and RAS-F, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.

View Management Team View Board of Directors

Investor Contact Information

Company

Qualigen Therapeutics, Inc.
2042 Corte del Nogal
Suite B
Carlsbad, CA 92011
T: 760-918-9165
F: 760-918-9127
ir@qualigeninc.com

Investor Relations

Atlanta Capital Partners, LLC
David Kugelman
President and CEO
T: (404) 856-9157
dk@atlcp.com

Investor Awareness, Inc.
Tony Schor
President
T: (847) 971-0922
tony@investorawareness.com

Transfer Agent

EQ Shareowner Services
PO Box 64874
St Paul, MN 55164
T: 800-468-9716
ShareownerOnline.com

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.